You have 9 free searches left this month | for more free features.

Condition

Extensive Stage Small Cell Lung Carcinoma (1)

Leukemia (1)

Metastatic Clear Cell Renal Cell Carcinoma (1)

Solid Tumor (1)

Overall Status

Completed (2)

Terminated (2)

Sign in for free

Phase

phase 1 (2)

phase 2 (2)

Sponsor

Eli Lilly and Company (3)

M.D. Anderson Cancer Center (1)

Collaborator

AstraZeneca (1)

Eli Lilly and Company (1)

High Impact Clinical Research Support Program (1)

Intervention

ly2510924 (4)

carboplatin (1)

cytarabine (1)

durvalumab (1)

etoposide (1)

idarubicin (1)

sunitinib (1)

Study Documents

Intervention Type

drug (4)

Funder Type

Industry (3)

Other (1)

Study Type

Interventional (4)

ly2510924

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Leukemia Trial in Houston (LY2510924, Idarubicin, Cytarabine)

Completed

Leukemia

LY2510924
+2 more

Houston, Texas

University of Texas MD Anderson Cancer Center

Nov 14, 2019

Solid Tumor Trial (LY2510924, Durvalumab)

Terminated

Solid Tumor

LY2510924
Durvalumab

(no location specified)

Jun 28, 2019

Extensive Stage Small Cell Lung Carcinoma Trial in United States (LY2510924, Carboplatin, Etoposide)

Completed

Extensive Stage Small Cell Lung Carcinoma

LY2510924
+2 more

Denver, Colorado
+14 more

Jun 28, 2019

Metastatic Clear Cell Renal Cell Carcinoma Trial in United States (LY2510924, Sunitinib)

Terminated

Metastatic Clear Cell Renal Cell Carcinoma

LY2510924
Sunitinib

Scottsdale, Arizona
+20 more

Jun 28, 2019